Skip to content
Exclusive CEO Interviews

Press Release

Make us preferred on Google
Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

✨ Onyx Summary Guardant Health launched the 34-member Single Namespace Working Group to establish an open standard for exabyte-scale data interoperability, creating a unified framework that links globally distributed data into a single namespace. The consortium’s transition to OASIS positions the standard for broad adoption, aiming to streamline

Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights

Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights

✨ Onyx Summary Legend Biotech reported third-quarter results highlighted by continued revenue growth for CARVYKTI, strengthened by updated survival data, expanded commercial manufacturing in Europe, and progress across its global clinical programs. The company ended the quarter with approximately $1.0 billion in cash and reduced its net loss year

enGene Announces Proposed Public Offering of Common Shares

enGene Announces Proposed Public Offering of Common Shares

✨ Onyx Summary enGene initiated an underwritten public offering of its common shares, with all shares offered by the company and an additional 15% overallotment option available to underwriters, subject to market conditions. The offering will be conducted under enGene’s effective shelf registration and supports ongoing advancement of its non-

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

✨ Onyx Summary Kyverna Therapeutics reported third-quarter progress across its neuroimmunology CAR T franchise, including positive interim Phase 2 data in generalized myasthenia gravis, advancement of its registrational trials in stiff person syndrome and gMG, and continued expansion into additional autoimmune indications, supported by upcoming milestones such as an early-

Neochromosome and GlobalBio Launch Pre-Transformed Antibody Libraries in Switchable Yeast Platform

Neochromosome and GlobalBio Launch Pre-Transformed Antibody Libraries in Switchable Yeast Platform

✨ Onyx Summary Neochromosome and GlobalBio introduced an integrated platform that combines ALTHEA antibody libraries with the neoSwitch yeast system to enable rapid, in-house biologics discovery with streamlined transitions from display to secretion. The collaboration reduces the cost and duration of antibody screening by eliminating traditional library construction steps and

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

✨ Onyx Summary enGene reported additional preliminary Phase 2 LEGEND data for detalimogene voraplasmid in high-risk BCG-unresponsive NMIBC, showing a 63% complete response rate at any time and improved 6-month CR rates under an amended protocol, alongside a favorable safety profile across 125 patients. The company has aligned

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

✨ Onyx Summary Lexicon Pharmaceuticals announced that its management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18, with live and archived access available through the company’s investor events page. THE WOODLANDS, TEXAS, NOV. 11, 2025 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

✨ Onyx Summary Kyverna Therapeutics announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on November 17, 2025, at 1:00 p.m. GMT. A live and archived webcast of the presentation will be available on the company’s investor relations website for 90 days.

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

✨ Onyx Summary enGene Holdings announced it will host a conference call and webcast on November 11, 2025, to present new preliminary data from the pivotal cohort of its ongoing LEGEND trial evaluating detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer. Supporting materials, including a slide deck and replay,

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

✨ Onyx Summary Lexicon Pharmaceuticals announced new data from the SOTA P CARDIA trial presented at AHA 2025 showing that sotagliflozin significantly improved cardiac structure, diastolic function, exercise capacity, and quality of life in heart failure patients with preserved ejection fraction and without diabetes. The findings, led by Mount Sinai’s

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health to Participate in Upcoming Investor Conferences

✨ Onyx Summary Guardant Health announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference in London on November 19 and the Piper Sandler 37th Annual Healthcare Conference in New York on December 2. Live and archived webcasts of both fireside chats will be available on the company’